<DOC>
	<DOCNO>NCT02593045</DOCNO>
	<brief_summary>The primary objective first human study ass safety tolerability increase intravenous ( IV ) dose single agent IPH4102 administer patient relapsed/refractory CTCL characterize dose limit toxicity ( DLT ) identify Maximum Tolerated Dose ( MTD ) .</brief_summary>
	<brief_title>Study IPH4102 Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas ( CTCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>1 . Patients relapsed/refractory , biopsyproven primary cutaneous Tcell lymphoma receive least two previous standard systemic therapy , MF/SS , stage IB IVB study entry . 2 . Centrally assessed KIR3DL2 expression tumor cell . 3 . Patients must follow minimum washout previous treatment : ≥12 week total skin electron beam irradiation , ≥4 week monoclonal antibody ( ≥8 week alemtuzumab ) , ≥3 week local radiation therapy , systemic cytotoxic anticancer therapy , treatment antineoplastic investigational agent ≥3 week systemic retinoids , interferon , vorinostat , romidepsin , fusion protein ≥3 week phototherapy ≥2 week topical therapy ( include steroid , retinoids , nitrogen mustard imiquimod ) Topical steroid ( maximum strength : medium potency ) oral steroid ( ≤10 mg prednisone equivalent/day ) allow , patient stable dose stable symptom least 4 week prior study entry . 4 . At least 18 year age . 5 . ECOG performance status ≤2 . 6 . Adequate baseline laboratory data : hemoglobin &gt; 9 g/dL , absolute neutrophil count ( ANC ) ≥1,000/µL , CD4+ Tcells ≥200/µL , platelets ≥50,000/µL , bilirubin ≤1.5 X upper limit normal ( ULN ) ≤3 X ULN patient Gilbert 's disease , serum creatinine ≤1.5 X ULN , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤3 X ULN . 7 . Women childbearing potential ( WOCBP ) must negative serum betaHCG pregnancy test result within seven day treatment must practice effective method contraception treatment least 9 month ( 270 day ) follow last dose study drug . 8 . Female patient postmenopausal surgically sterile . 9 . Male patient agree practice effective barrier contraception . 10 . Ability understand willingness sign write informed consent document . 11 . No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule . 1 . Patients limited disease ( MF/SS : stage IA ) central nervous system ( CNS ) disease . 2 . Clinical relevant AEs laboratory result related previous antineoplastic therapy resolve NCICTCAE grade ≤1 . 3 . Concomitant corticosteroid use , systemic topical , treatment skin disease . However , topical steroid ( maximum strength : medium potency ) oral steroid ( ≤10 mg prednisone equivalent/day ) allow , patient stable dose stable symptom least 4 week prior study entry . 4 . Patients undergone major surgery &lt; 4 week prior start study drug . 5 . Patients undergone stem cell transplantation . 6 . Patients know NCI CTCAE Grade 3 high ( require IV antibiotic ) active systemic cutaneous viral , bacterial , fungal infection . 7 . Patients Hepatitis B Hepatitis C antibody positive . 8 . Patients know HIVpositive . 9 . Prior hypersensitivity reaction monoclonal antibody , therapeutic protein , immunotherapy . 10 . Patients history malignancy past three year . ( The follow exempt threeyear limit : nonmelanoma skin cancer , Lymphomatoid papulosis , curatively treat localized prostate cancer , curatively treat localize breast cancer , resect thyroid cancer , biopsy proven cervical intraepithelial neoplasia cervical carcinoma situ ) . 11 . Patients currently pregnant breastfeeding . 12 . Patients congestive heart failure , Class III IV , New York Heart Association ( NYHA ) criterion . 13 . Patients serious underlying medical condition would impair ability receive tolerate plan treatment . 14 . Patients dementia alter mental status would preclude understand render informed consent document .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>